Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

American Heart Association In Brief

This article was originally published in The Gray Sheet

Executive Summary

Study results on ICD programming, biventricular pacing and more from the 2012 AHA Scientific Sessions in Los Angeles.

You may also be interested in...



FDA Approves Medtronic’s CRT Devices For Less Severe Heart Failure

Following the advice of its advisory panel, FDA expanded the indication for two Medtronic cardiac resynchronization pacemakers and eight cardiac resynchronization defibrillators to include patients with atrioventricular block and less severe heart failure.

FDA Panel Narrowly Favors Expanding Patient Population For Biventricular Pacing

With the help of a tie-breaker vote, the Circulatory System Devices Advisory Panel said the benefits outweigh the risks of expanding the indications for biventricular cardiac resynchronization therapy devices to include patients at risk for developing new or worsened heart failure because of their need for right ventricular pacing. Medtronic is seeking the expansion in a submission before FDA.

FDA Panel Narrowly Favors Expanding Patient Population For Biventricular Pacing

With the help of a tie-breaker vote, the Circulatory System Devices Panel said the benefits outweigh the risks of expanding the indications for biventricular cardiac resynchronization therapy devices to include patients at risk for developing new or worsened heart failure because of their need for right ventricular pacing. Medtronic is seeking the expansion in a submission before FDA.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT031716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel